A single-arm, multicenter phase II clinical study to evaluate the efficacy of Ensartinib in patients with advanced or metastatic non-small cell lung cancer harboring MET 14 exon skipping mutation
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Ensartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Nov 2024 New trial record